Pediatric Tacrolimus-Induced Reversible Cerebral Vasoconstriction Syndrome after Heart Transplantation

Abstract

Reversible cerebral vasoconstriction syndrome (RCVS) is a rare post-organ transplantation complication. While uncommon, complications of post-transplant RCVS can be devastating, with sequelae including ischemic or hemorrhagic stroke and potential significant neurological morbidity. There is a paucity of literature on tacrolimus-mediated RCVS, particularly in the pediatric population. To date, only five case reports have been published, with the youngest patient being 15 years of age. We report the youngest case to date of post-heart transplant tacrolimus-induced RCVS in a 6-year-old male. The present case highlights the necessity of urgent imaging in suspected cases of RCVS, the potential diagnostic challenges surrounding the etiology of headache, the benefits of treating underlying cerebral vasospasm, and the importance of rapid discontinuation of the offending agent for the remission of symptoms and prevention of long-term sequelae.

Keywords

reversible cerebral vasoconstriction syndrome - post-heart transplant - tacrolimus

Note

Consent was obtained from the patient's family to include relevant medical information and imaging in this report.

Publication History

Received: 10 November 2021

Accepted: 20 February 2022

Article published online:
22 June 2022

• References

• 1 Ducros A. Reversible cerebral vasoconstriction syndrome. Lancet Neurol 2012; 11 (10) 906-917
• 2 Ducros A, Fiedler U, Porcher R, Boukobza M, Stapf C, Bousser MG. Hemorrhagic manifestations of reversible cerebral vasoconstriction syndrome: frequency, features, and risk factors. Stroke 2010; 41 (11) 2505-2511
• 3 Cappelen-Smith C, Calic Z, Cordato D. Reversible cerebral vasoconstriction syndrome: recognition and treatment. Curr Treat Options Neurol 2017; 19 (06) 21
• 4 Magid-Bernstein J, Omran SS, Parikh NS, Merkler AE, Navi B, Kamel H. RCVS: symptoms, incidence, and resource utilization in a population-based US cohort. Neurology 2021; 97 (03) e248-e253
• 5 Chen SP, Fuh JL, Wang SJ. Reversible cerebral vasoconstriction syndrome: an under-recognized clinical emergency. Ther Adv Neurol Disord 2010; 3 (03) 161-171
• 6 Ospel JM, Wright CH, Jung R. et al. Intra-arterial verapamil treatment in oral therapy-refractory reversible cerebral vasoconstriction syndrome. AJNR Am J Neuroradiol 2020; 41 (02) 293-299
• 7 Maeda S, Saito S, Toda K. et al. A case of tacrolimus-induced reversible cerebral vasoconstriction syndrome after heart transplantation. Gen Thorac Cardiovasc Surg 2020; 68 (12) 1483-1486
• 8 Kodama S, Mano T, Masuzawa A. et al. Tacrolimus-induced reversible cerebral vasoconstriction syndrome with delayed multi-segmental vasoconstriction. J Stroke Cerebrovasc Dis 2017; 26 (05) e75-e77
• 9 Ban SP, Hwang G, Kim CH, Kwon OK. Reversible cerebral vasoconstriction syndrome combined with posterior reversible encephalopathy syndrome after heart transplantation. J Clin Neurosci 2017; 42: 118-121
• 10 Kumai Y, Seguchi O, Sato T. et al. Reversible cerebral vasoconstriction syndrome after heart transplantation: a case report. Transplant Proc 2017; 49 (10) 2415-2418
• 11 Park CS, Park JJ. Two rare neurologic complications after heart transplantation: Posterior reversible encephalopathy syndrome, followed by reversible cerebral vasoconstriction syndrome. J Heart Lung Transplant 2016; 35 (07) 940-943
• 12 Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int 2000; 13 (05) 313-326
• 13 Ducros A, Boukobza M, Porcher R, Sarov M, Valade D, Bousser MG. The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain 2007; 130 (Pt 12): 3091-3101
• 14 Stary JM, Wang BH, Moon SJ, Wang H. Dramatic intracerebral hemorrhagic presentations of reversible cerebral vasoconstriction syndrome: three cases and a literature review. Case Rep Neurol Med 2014; 2014: 782028
• 15 Miller TR, Shivashankar R, Mossa-Basha M, Gandhi D. Reversible cerebral vasoconstriction syndrome, part 1: epidemiology, pathogenesis, and clinical course. AJNR Am J Neuroradiol 2015; 36 (08) 1392-1399
• 16 Singhal AB, Hajj-Ali RA, Topcuoglu MA. et al. Reversible cerebral vasoconstriction syndromes: analysis of 139 cases. Arch Neurol 2011; 68 (08) 1005-1012
• 17 Singhal AB, Topcuoglu MA. Glucocorticoid-associated worsening in reversible cerebral vasoconstriction syndrome. Neurology 2017; 88 (03) 228-236
• 18 Elstner M, Linn J, Müller-Schunk S, Straube A. Reversible cerebral vasoconstriction syndrome: a complicated clinical course treated with intra-arterial application of nimodipine. Cephalalgia 2009; 29 (06) 677-682
• 19 Al-Mufti F, Dodson V, Wajswol E. et al. Chemical angioplasty for medically refractory reversible cerebral vasoconstriction syndrome. Br J Neurosurg 2018; 32 (04) 431-435